Adil Daud, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7392
ORCID ORCID Icon0000-0002-6617-8421 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Government Medical College, NagpurMBBS12/1985Medicine
    Cleveland Clinic, Cleveland, OHPost Doc Fellowship12/1989Biochemistry
    Indiana University, Indianapolis INPost Doc Fellowship6/1994Molecular Biology
    Indiana University, Indianapolis INResidency06/1997Internal Medicine

    Collapse Overview 
    Collapse Overview
    Immune therapy and Clinical Trials

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. J Clin Oncol. 2021 Jun 17; JCO2100943. Huppert LA, Daud AI. PMID: 34138634.
      View in: PubMed   Mentions:    Fields:    
    2. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J Exp Med. 2021 Apr 05; 218(4). Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, Sharpe AH, Singer M. PMID: 33651880.
      View in: PubMed   Mentions: 3     Fields:    
    3. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021 Apr; 9(4). Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. PMID: 33879601.
      View in: PubMed   Mentions:    Fields:    
    4. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research Foundation . PMID: 33414132.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021 Feb; 144:182-191. Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, Hodi FS, Wolchok JD, Mitchell TC, Hersey P, Dronca R, Joseph RW, Boutros C, Min L, Long GV, Schachter J, Puzanov I, Dummer R, Lin J, Ibrahim N, Diede SJ, Carlino MS, Joshua AM. PMID: 33360855.
      View in: PubMed   Mentions: 1     Fields:    
    6. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. PMID: 33020646.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    7. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020 10 02; 5(52). Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. PMID: 33008914.
      View in: PubMed   Mentions: 9     Fields:    
    8. Layilin augments integrin activation to promote antitumor immunity. J Exp Med. 2020 09 07; 217(9). Mahuron KM, Moreau JM, Glasgow JE, Boda DP, Pauli ML, Gouirand V, Panjabi L, Grewal R, Luber JM, Mathur AN, Feldman RM, Shifrut E, Mehta P, Lowe MM, Alvarado MD, Marson A, Singer M, Wells J, Jupp R, Daud AI, Rosenblum MD. PMID: 32539073.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    9. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. PMID: 32725204.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    10. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncol. 2020 08 01; 6(8):1256-1264. Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O. PMID: 32672795.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    11. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    12. Treatment of Metastatic Melanoma With Leptomeningeal Disease Using Intrathecal Immunotherapy. JCO Oncol Pract. 2020 11; 16(11):757-759. Huppert LA, Melisko ME, Glastonbury CM, Khanafshar E, Daud AI. PMID: 32603255.
      View in: PubMed   Mentions:
    13. ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4131-4132. Mahuron KM, Levine LS, Daud AI. PMID: 32488511.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. Ann Surg Oncol. 2020 Oct; 27(11):4122-4130. Levine LS, Mahuron KM, Tsai KK, Wu C, Mattis DM, Pauli ML, Oglesby A, Lee JC, Spitzer MH, Krummel MF, Algazi AP, Rosenblum MD, Alvarado M, Daud AI. PMID: 32488521.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clin Cancer Res. 2020 06 15; 26(12):2827-2837. Algazi AP, Twitty CG, Tsai KK, Le M, Pierce R, Browning E, Hermiz R, Canton DA, Bannavong D, Oglesby A, Francisco M, Fong L, Pittet MJ, Arlauckas SP, Garris C, Levine LP, Bifulco C, Ballesteros-Merino C, Bhatia S, Gargosky S, Andtbacka RHI, Fox BA, Rosenblum MD, Daud AI. PMID: 32376655.
      View in: PubMed   Mentions: 7     Fields:    
    16. Prognostic Biomarkers for Melanoma Immunotherapy. Curr Oncol Rep. 2020 02 11; 22(3):25. Twitty CG, Huppert LA, Daud AI. PMID: 32048065.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    17. Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI Insight. 2019 12 19; 4(24). Lowe MM, Boothby I, Clancy S, Ahn RS, Liao W, Nguyen DN, Schumann K, Marson A, Mahuron KM, Kingsbury GA, Liu Z, Munoz Sandoval P, Rodriguez RS, Pauli ML, Taravati K, Arron ST, Neuhaus IM, Harris HW, Kim EA, Shin US, Krummel MF, Daud A, Scharschmidt TC, Rosenblum MD. PMID: 31852848.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    18. Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunol Res. 2020 02; 8(2):246-254. Greaney SK, Algazi AP, Tsai KK, Takamura KT, Chen L, Twitty CG, Zhang L, Paciorek A, Pierce RH, Le MH, Daud AI, Fong L. PMID: 31852717.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    19. Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers. Am J Clin Dermatol. 2019 Dec; 20(6):781-796. Oglesby A, Algazi AP, Daud AI. PMID: 31228012.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    20. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. PMID: 31732523.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    21. Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clin Cancer Res. 2020 02 01; 26(3):598-607. Bhatia S, Longino NV, Miller NJ, Kulikauskas R, Iyer JG, Ibrani D, Blom A, Byrd DR, Parvathaneni U, Twitty CG, Campbell JS, Le MH, Gargosky S, Pierce RH, Heller R, Daud AI, Nghiem P. PMID: 31582519.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    22. An analysis of genetic heterogeneity in untreated cancers. Nat Rev Cancer. 2019 11; 19(11):639-650. Reiter JG, Baretti M, Gerold JM, Makohon-Moore AP, Daud A, Iacobuzio-Donahue CA, Azad NS, Kinzler KW, Nowak MA, Vogelstein B. PMID: 31455892.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    23. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019 09; 20(9):1239-1251. Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV. PMID: 31345627.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansCTClinical Trials
    24. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members , Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. PMID: 31267972.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    25. PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. J Natl Compr Canc Netw. 2019 07 01; 17(7):778-783. Tsai KK, Khurana N, McCalmont T, Daud A, Bastian B, Yeh I. PMID: 31319387.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma. Pigment Cell Melanoma Res. 2019 07; 32(4):603-606. Algazi AP, Rotow J, Posch C, Ortiz-Urda S, Pelayo A, Munster PN, Daud A. PMID: 30801911.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    27. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019 04 18; 177(3):556-571.e16. Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF. PMID: 30955881.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
    28. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019 03 20; 37(9):693-702. Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. PMID: 30726175.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCTClinical Trials
    29. Clonal Deletion of Tumor-Specific T Cells by Interferon-? Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade. Immunity. 2019 02 19; 50(2):477-492.e8. Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon AJ, Kinsbury GA, Fong L. PMID: 30737146.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    30. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. Front Med (Lausanne). 2018; 5:351. Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA. PMID: 30631766.
      View in: PubMed   Mentions:
    31. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-? and IL-12. Immunity. 2018 12 18; 49(6):1148-1161.e7. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. PMID: 30552023.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansAnimalsCells
    32. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 30510087.
      View in: PubMed   Mentions: 5     Fields:    
    33. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018 09; 119(6):670-674. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M. PMID: 30202085.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    34. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Eur J Cancer. 2018 09; 101:236-243. Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A. PMID: 30096704.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    35. The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma. Sci Rep. 2018 Jul 19; 8(1):10902. Sanlorenzo M, Vujic I, Esteve-Puig R, Lai K, Vujic M, Lin K, Posch C, Dimon M, Moy A, Zekhtser M, Johnston K, Gho D, Ho W, Gajjala A, Oses Prieto J, Burlingame A, Daud A, Rappersberger K, Ortiz-Urda S. PMID: 30026510.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    36. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 11 01; 24(21):5250-5260. Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N. PMID: 30021908.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    37. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018 08; 24(8):1178-1191. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, Nelson AE, Loo K, Kumar R, Rosenblum MD, Alvarado MD, Wolf DM, Bogunovic D, Bhardwaj N, Daud AI, Ha PK, Ryan WR, Pollack JL, Samad B, Asthana S, Chan V, Krummel MF. PMID: 29942093.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    38. Negative but not futile: MAGE-A3 immunotherapeutic for melanoma. Lancet Oncol. 2018 07; 19(7):852-853. Daud AI. PMID: 29908989.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Melanocytic Neoplasms, Introduction. Semin Cutan Med Surg. 2018 Jun; 37(2):87. Daud AI. PMID: 30040084.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Immunotherapy for melanoma. Semin Cutan Med Surg. 2018 Jun; 37(2):127-131. Cuevas LM, Daud AI. PMID: 30040090.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series. J Immunother Cancer. 2018 05 30; 6(1):43. Xu MJ, Wu S, Daud AI, Yu SS, Yom SS. PMID: 29848371.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    42. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 10 15; 24(20):4960-4967. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. PMID: 29685882.
      View in: PubMed   Mentions: 54     Fields:    
    43. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018; 14(9):2178-2182. Humphries A, Daud A. PMID: 29494275.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    44. Revisiting RECIST: the case of treatment beyond progression. Lancet Oncol. 2018 02; 19(2):157-159. Daud AI. PMID: 29361472.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. PMID: 29283791.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    46. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer. 2018 03; 91:168-170. Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C. PMID: 29224903.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    47. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018 01; 31(1):110-114. Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. PMID: 28921907.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    48. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. PMID: 28961465.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    49. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340. Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. PMID: 29028788.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    50. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy. 2017 12; 9(16):1309-1321. Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A. PMID: 29064334.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    51. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 11; 86:296-304. Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. PMID: 29059635.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    52. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 03 01; 36(7):667-673. Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. PMID: 28991513.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    53. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21; 390(10105):1853-1862. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. PMID: 28822576.
      View in: PubMed   Mentions: 282     Fields:    Translation:HumansCTClinical Trials
    54. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. PMID: 28724802.
      View in: PubMed   Mentions: 17     Fields:    
    55. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018 02 01; 36(4):383-390. Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. PMID: 28671856.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    56. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 07; 22(7):823-833. Daud A, Tsai K. PMID: 28526719.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    57. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 05; 5(5):417-424. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. PMID: 28411193.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCellsCTClinical Trials
    58. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A. PMID: 28324889.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    59. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. PMID: 28103611.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    60. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017 01 04; 10(1):3. Daud A, Gill J, Kamra S, Chen L, Ahuja A. PMID: 28052762.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    61. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017 Jan/Feb; 23(1):3-9. Loo K, Daud AI. PMID: 28114249.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    62. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. PMID: 27863197.
      View in: PubMed   Mentions: 174     Fields:    Translation:HumansCTClinical Trials
    63. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud AI. PMID: 27660712.
      View in: PubMed   Mentions: 10     Fields:    
    64. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016 11; 67:46-54. Schadendorf D, Dummer R, Hauschild A, Robert C, Hamid O, Daud A, van den Eertwegh A, Cranmer L, O'Day S, Puzanov I, Schachter J, Blank C, Salama A, Loquai C, Mehnert JM, Hille D, Ebbinghaus S, Kang SP, Zhou W, Ribas A. PMID: 27596353.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    65. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. PMID: 27533448.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    66. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 09 01; 126(9):3447-52. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD. PMID: 27525433.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansCells
    67. Part II: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 06; 8(7):761-2. Daud AI. PMID: 27349974.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    68. Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy. 2016 06; 8(7):775-84. Loo K, Daud A. PMID: 27349977.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    69. Part I: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 Jun; 8(6):675-6. Daud AI. PMID: 27197535.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    70. A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. Oncology (Williston Park). 2016 May; 30(5):442-3. Chen L, Daud A. PMID: 27188675.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. Pembrolizumab for melanoma- safety profile and future trends. Expert Opin Drug Saf. 2016 Jun; 15(6):727-9. Daud A, Nandoskar P. PMID: 27056241.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. PMID: 27092830.
      View in: PubMed   Mentions: 303     Fields:    Translation:HumansCTClinical Trials
    73. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30; 374(26):2542-52. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PMID: 27093365.
      View in: PubMed   Mentions: 348     Fields:    Translation:HumansCTClinical Trials
    74. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. PMID: 26951310.
      View in: PubMed   Mentions: 212     Fields:    Translation:HumansCTClinical Trials
    75. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. PMID: 26811525.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    76. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. JAAD Case Rep. 2015 Nov; 1(6):S23-5. Garrett GL, He SY, Sabouni N, Daud A, Arron ST. PMID: 27051803.
      View in: PubMed   Mentions:
    77. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. JAMA Dermatol. 2015 Nov; 151(11):1206-1212. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. PMID: 26222619.
      View in: PubMed   Mentions: 117     Fields:    Translation:Humans
    78. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015 Oct 31; 8:123. Tsai KK, Daud AI. PMID: 26518223.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    79. Current and Emerging Perspectives on Immunotherapy for Melanoma. Semin Oncol. 2015 Dec; 42 Suppl 3:S3-S11. Daud A. PMID: 26598057.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    80. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. PMID: 26392102.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansAnimalsCTClinical Trials
    81. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert Opin Pharmacother. 2015; 16(14):2257-63. Zia Y, Chen L, Daud A. PMID: 26331795.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    82. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. PMID: 26115796.
      View in: PubMed   Mentions: 476     Fields:    Translation:HumansCTClinical Trials
    83. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 01; 21(19):4286-93. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. PMID: 25977344.
      View in: PubMed   Mentions: 217     Fields:    Translation:HumansCTClinical Trials
    84. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25; 372(26):2521-32. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators . PMID: 25891173.
      View in: PubMed   Mentions: 1575     Fields:    Translation:HumansCTClinical Trials
    85. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75. Tsai KK, Daud AI. PMID: 25802230.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    86. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. PMID: 25605849.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsCTClinical Trials
    87. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell. 2014 Dec 08; 26(6):938. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. PMID: 28898680.
      View in: PubMed   Mentions: 36     Fields:    
    88. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014 Nov; 150(11):1209-12. Chen FW, Tseng D, Reddy S, Daud AI, Swetter SM. PMID: 25142409.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    89. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. PMID: 25440439.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    90. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. PMID: 25446897.
      View in: PubMed   Mentions: 290     Fields:    Translation:HumansAnimalsCells
    91. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. PMID: 25287827.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    92. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. PMID: 25034862.
      View in: PubMed   Mentions: 592     Fields:    Translation:HumansCTClinical Trials
    93. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. PMID: 25037139.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    94. Combinatorial approach to treatment of melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):601-12. Ashworth MT, Daud AI. PMID: 24880950.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    95. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M, National Comprehensive Cancer Network . PMID: 24812131.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    96. Melanoma immunotherapy. . 2014 Jun 01; 15(6):665-74. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. PMID: 24651672.
      View in: PubMed   Mentions:
    97. Management of a patient with advanced BRAF-mutant melanoma. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):315-9; quiz 319. Ashworth MT, Daud A. PMID: 24616537.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. PMID: 24374975.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    99. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014; 10(11):3111-6. Tsai KK, Zarzoso I, Daud AI. PMID: 25625924.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    100. Reply to M.-E. Percival et al and L.B. Saltz. J Clin Oncol. 2013 Jul 01; 31(19):2515-6. Daud AI. PMID: 23967490.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. PMID: 23724846.
      View in: PubMed   Mentions: 1329     Fields:    Translation:HumansCTClinical Trials
    102. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):395-407. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M, National Comprehensive Cancer Network (NCCN) . PMID: 23584343.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    103. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. PMID: 23431193.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    104. Removing the unknown from the carcinoma of unknown primary. J Clin Oncol. 2013 Jan 10; 31(2):174-5. Daud AI. PMID: 23233703.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    105. Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother. 2012 Nov 01; 8(11):1734-8. Cha E, Daud A. PMID: 23151447.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    106. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. PMID: 23020132.
      View in: PubMed   Mentions: 929     Fields:    Translation:HumansCellsCTClinical Trials
    107. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. PMID: 22694288.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    108. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9. Chong K, Daud A, Ortiz-Urda S, Arron ST, UCSF High Risk Skin Cancer Program . PMID: 22640435.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    109. Melanoma. J Natl Compr Canc Netw. 2012 Mar; 10(3):366-400. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, National Comprehensive Cancer Network . PMID: 22393197.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    110. Beyond BRAF in melanoma. Curr Top Microbiol Immunol. 2012; 355:99-117. Daud A, Bastian BC. PMID: 21826607.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    111. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012 Feb 15; 18(4):1092-100. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. PMID: 22179664.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    112. BEAM trial: lighting the way ahead? J Clin Oncol. 2012 Jan 01; 30(1):6-7. Daud AI. PMID: 22124100.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov; 20(11):1565-74. Munster PN, Daud AI. PMID: 21985236.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    114. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. PMID: 21994418.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    115. An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol. 2011 Oct; 38(10):801-7. Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS. PMID: 21883364.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    116. Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol. 2011 May 01; 103(6):538-49. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. PMID: 21480247.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    117. NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol. 2011 May; 147(5):626-7. Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. PMID: 21576590.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    118. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. PMID: 21245693.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    119. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct; 33(8):817-27. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. PMID: 20842055.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    120. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010 Aug 17; 2:197-211. Algazi AP, Soon CW, Daud AI. PMID: 21188111.
      View in: PubMed   Mentions:
    121. New horizons in melanoma treatment: targeting molecular pathways. Ochsner J. 2010; 10(2):93-8. Soon CW, Algazi AP, Cha EN, Daud AI. PMID: 21603363.
      View in: PubMed   Mentions:
    122. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun; 19(3):167-75. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. PMID: 19434004.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    123. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. PMID: 19349552.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCTClinical Trials
    124. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr 01; 15(7):2488-96. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. PMID: 19318486.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCellsCTClinical Trials
    125. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 01; 15(7):2479-87. Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. PMID: 19318485.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    126. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 2008 Dec 15; 14(24):8302-7. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB. PMID: 19088048.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansCellsCTClinical Trials
    127. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20; 26(36):5896-903. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. PMID: 19029422.
      View in: PubMed   Mentions: 198     Fields:    Translation:HumansCTClinical Trials
    128. State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer. 2008 Oct 01; 113(7 Suppl):1728-43. Demierre MF, Sabel MS, Margolin KA, Daud AI, Sondak VK. PMID: 18798543.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    129. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008 Nov 10; 26(32):5198-203. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. PMID: 18824702.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCTClinical Trials
    130. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 Apr; 63(5):903-10. Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB. PMID: 18682950.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    131. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008 Jul 01; 26(19):3235-41. Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. PMID: 18591558.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    132. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control. 2008 Jul; 15(3):192-4. Zager JS, Daud AI. PMID: 18596670.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. Activated stat-3 in melanoma. Cancer Control. 2008 Jul; 15(3):196-201. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. PMID: 18596671.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    134. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008 Apr 28; 1:13. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. PMID: 18442402.
      View in: PubMed   Mentions: 233     Fields:    
    135. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 01; 13(19):5855-61. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. PMID: 17908979.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    136. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007 Jul; 14(3):285-94. Homsi J, Daud AI. PMID: 17615535.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    137. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May 20; 25(15):1979-85. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. PMID: 17513804.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    138. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 Jan; 11(1):91-100. Homsi J, Cubitt C, Daud A. PMID: 17150037.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    139. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol. 2007 Apr; 14(4):1416-23. Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. PMID: 17195911.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    140. Melanoma. J Natl Compr Canc Netw. 2006 Aug; 4(7):666-84. Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ, National Comprehensive Cancer Network . PMID: 16884669.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    141. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 01; 12(15):4645-51. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. PMID: 16899614.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    142. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul; 13(3):211-7. Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. PMID: 16885917.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    143. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res. 2006 May 15; 12(10):3177-83. Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. PMID: 16707618.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    144. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci. 2006 Jan 01; 11:1-14. Riker AI, Jove R, Daud AI. PMID: 16146709.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    145. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec 01; 11(23):8467-75. Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. PMID: 16322310.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    146. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. . 2005 Dec; 4(12):1993-2000. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 16373714.
      View in: PubMed   Mentions:
    147. Cutaneous melanoma: prognostic factors. Cancer Control. 2005 Oct; 12(4):223-9. Homsi J, Kashani-Sabet M, Messina JL, Daud A. PMID: 16258493.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    148. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 01; 65(9):3815-22. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. PMID: 15867379.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansAnimalsCells
    149. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr 15; 11(8):3009-16. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. PMID: 15837755.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    150. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol. 2004 Aug 01; 22(15):3194-5. Naing A, Messina JL, Vrionis FR, Daud AI. PMID: 15284274.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    151. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15; 92(2):223-37. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. PMID: 15108350.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    152. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002 Oct 10; 21(46):7001-10. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. PMID: 12370822.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCells
    153. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002 Aug; 8(8):2505-11. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. PMID: 12171876.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    Adil's Networks
    Concepts (435)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (85)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.0.0-839-g49dc76ac on PROFILES-PWEB01.

    Copyright © The Regents of the University of California